Alkem Laboratories launches semaglutide injection in India

23 Mar 2026 Evaluate

Alkem Laboratories has launched semaglutide injection in India under the brand names Semasize, Obesema and Hepaglide. Semaglutide is administered as a subcutaneous injection, once weekly.

The company has launched its semaglutide pre-filled disposable injection pen at a price starting Rs 1,800 for a month’s dosage, which translates into a weekly cost of Rs 450.

Through an affordable pricing, Alkem aims to lower barriers to initiation and expand access to this therapy in India. Alkem has received approval from the Drug Controller General of India (DCGI) for manufacturing and marketing semaglutide for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise, subsequent to a review of its Phase 3 clinical trials conducted in India. Semaglutide is a prescription product and should be taken under appropriate medical supervision.

Apart from disposable pen, Alkem is offering reusable injection pen for semaglutide administration for higher maintenance doses. The reusable pen enables patients to replace only the medication cartridge rather than purchasing a new disposable pen each time, thereby reducing cost and helping better patient adherence to treatment.

Alkem Laboratories is among India’s leading global pharmaceutical companies. The company develops, manufactures and markets high-quality pharmaceutical products across all major therapeutic segments.

Alkem Laboratories Share Price

5343.50 -91.50 (-1.68%)
27-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.65
Dr. Reddys Lab 1281.95
Cipla 1242.65
Zydus Lifesciences 896.60
Lupin 2334.95
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×